1. Карпенко Л.И., Иванисенко В.А., Пика И.А., Чикаев Н.А., Ерошкин А.М., Меламед Н.В., Веремейко Т.А., Ильичев А.А. Анализ чужеродных эпитопов, встроенных в НВсAg. Возможные пути решения проблемы самоорганизации химерных коровых частиц. Молекул. биология. 2000; 34 (2): 223–229.
Karpenko L.I., Ivanisenko V.A., Pika I.A., Chikaev N.A., Eroshkin A.M., Melamed N.V., Veremeyko T.A., Il’ichev A.A. Analysis of foreign epitope inserts in HBcAg. Approaches to solving the problem of core particle self-assembly. Mol. Biol. (Mosc.) 2000; 34 (2): 194–199.
2. Рудометов А.П., Андреева Н.Б., Чикаев А.Н., Щербакова Н.С., Каплина О.Н., Карпенко Л.И. Антигенные свойства искусственного полиэпитопного ВИЧ-иммуногена. Сиб. науч. мед. журн. 2018; 8 (4): 37–43.
Rudometov A.P., Andreeva N.B., Chikaev A.N., Shcherbakova N.S., Kaplina O.N., Karpenko L.I. Antigenic properties of an artificial polyepitopic HIV immunogen. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2018; 8 (4): 37–43. [In Russian].
3. Рудометов А.П., Чикаев А.Н., Андреева Н.Б., Щербакова Н.С., Лебедев Л.Р., Каплина О.Н., Ильичев А.А., Карпенко Л.И. Химерный белок НВсАg, несущий миметик эпитопа, узнаваемого моноклональным антителом VRC01. Вопр. биол., мед. и фармац. химии. 2018; 21 (4): 46–51.
Rudometov A.P., Chikaev A.N., Andreeva N.B., Shcherbakova N.S., Lebedev L.R., Kaplina O.N., Il’ichev A.A., Karpenko L.I. Chimeric protein HBcAg carrying the epitope mimetic recognized by the monoclonal antibody VRC01. Voprosy biologicheskoy, meditsinskoy i farmatsevticheskoy khimii = Problems of Biological, Medical and Pharmaceutical Chemistry. 2018; 21 (4): 46–51. [In Russian].
4. Arora U., Tyagi P., Swaminathan S., Khannaet N. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J. Nanobiotechnol. 2012; 10 (30): 1–6.
5. Baryshev P.B., Bogachev V.V., Gashnikova N.M. HIV-1 genetic diversity in Russia: CRF63_02A1, a new HIV type 1 genetic variant spreading in Siberia. AIDS Res. Hum. Retroviruses. 2014; 30 (6): 592–597.
6. Burton D.R., Mascola J.R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 2015; 16 (6): 571–576.
7. Frietze K.M., Peabody D.S., Chackerian B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 2016; 18: 44–49.
8. Grgacic E.V.L., Anderson D.A. Virus-like particles: passport to immune recognition. Methods. 2006; 40 (1): 60–65.
9. Haynes B.F., Burton D.R. Developing an HIV vaccine. Science. 2017; 355 (6330): 1129–1130.
10. Jegerlehner A., Tissot A., Lechner F. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine. 2002; 20 (25–26): 3104–3112.
11. Jennings G.T., Bachmann M.F. The coming of age of virus-like particle vaccines. Biol. Chem. 2008; 389 (5): 521–536.
12. Karpenko L.I., Ivanisenko V.A., Pika I.A. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids. 2000; 18 (4): 329–337.
13. Korber B., Hraber P., Wagh K., Hahn B.H. Polyvalent vaccine approaches to combat HIV-1 diversity. Immunol. Rev. 2017; 275 (1): 230–244.
14. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 2008; 38 (5): 1404–1413.
15. McCoy L.E., Burton D.R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 2017; 275 (1): 11–20.
16. Medina-Ramírez M., Garces F., Escolano A., Skog P., de Taeye S.W., Del Moral-Sanchez I., McGuire A.T., Yasmeen A., Behrens A.J., Ozorowski G. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J. Exp. Med. 2017; 214 (9): 2573–2590.
17. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 2008; 72: 54–84.
18. Muñoz-Barroso I., Salzwedel K., Hunter E., Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J. Virol. 1999; 73 (7): 6089–6092.
19. Pumpens P., Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology. 2001; 44. 98–114.
20. Pumpens P., Grens E. The true story and advantages of the famous Hepatitis B virus core particles: Outlook 2016. Mol. Biol. 2016; 50: 489–509.
21. Sahay B., Nguyen C.Q., Yamamoto J.K. Conserved HIV epitopes for an effective HIV vaccine. J. Clin. Cell. Immunol. 2017; 8 (4): 1–27.
22. Shcherbakova N.S., Shalamova L.A., Delgado E., Fernández-García A., Vega Y., Karpenko L.I., Ilyichev A.A., Sokolov Y.V., Shcherbakov D.N., Pérez-Álvarez L., Thomson M.M. Molecular epidemiology, phylogeny, and phylodynamics of CRF63_02A1, a recently originated HIV-1 circulating recombinant form spreading in Siberia. AIDS Res. Hum. Retroviruses. 2014; 30 (9): 912–919.
23. Whitacre D.C., Lee B.O., Milich D.R. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev. Vaccines. 2009; 8 (11): 1565–1573.
24. Zabel F., Kündig T.M., Bachmann M.F. Virus-induced humoral immunity: on how B cell responses are initiated. Curr. Opin. Virol. 2013; 3 (3): 357–362.